Research and Markets: Acute Myeloid Leukemia (AML) - Pipeline Assessment and Market Forecasts to 2017

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/353254/acute_myeloid_leuk) has announced the addition of GlobalData 's new report "Acute Myeloid Leukemia (AML) - Pipeline Assessment and Market Forecasts to 2017" to their offering.

Acute Myeloid Leukemia (AML) - Pipeline Assessment and Market Forecasts to 2017 is an essential source of information and analysis on the global AML therapeutics market. The report identifies the key trends shaping and driving the global AML therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global AML therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

The authors estimated the global AML therapeutics market to be worth $174m in 2009. It is expected to grow to $279m with a Compound Annual Growth Rate (CAGR) of 6.1% by 2017. This growth is primarily attributed to the increase in the prevalence of the disease due to the increasing elderly population and the presence of a strong pipeline with many emerging therapies. Pfizer and Genzyme remain the market leaders within the global AML therapeutics market. There is a high level of unmet need in the current AML therapeutics market in terms of both safety and efficacy.

The AML Therapeutics Market is Forecast to Show Increased Growth until 2017

The authors estimated the global Acute Myeloid Leukemia (AML) therapeutics market to be worth $174m in 2009. It is expected to grow to $279m with a Compound Annual Growth Rate (CAGR) of 6.1% by 2017. This growth is primarily attributed to the increase in the prevalence due to the increasing elderly population and the presence of a strong pipeline with many emerging therapies. Pfizer and Genzyme are the market leaders within the global AML therapeutics market. There is a high level of unmet need in the current AML market in terms of both safety and efficacy.

AML Therapeutics Market, Global, Revenue ($m), 2001-2017

The prevalence rate for AML globally was found to be 0.1% or 827,671 people. AML is a cancerous condition primarily associated with the elderly. The onset of the condition mostly occurs between the ages of 50 and 65. The yearly incidence of new AML diagnoses in the US is 17.6/100,000 for people 65 years of age or older, compared to 1.8/100,000 for people less than 65 years. The incidence of AML increases with age. A significant increase in AML incidence has occurred over the past 10 years, especially in the elderly population. From the above data it is clear that the greater number of AML patients seeking treatment in the next five to ten years will result in increased usage of therapeutics drugs which in turn will drive the AML therapeutics market.

Key Topics Covered:

  • 1 Table of contents
  • 2 AML Therapeutics Market: Introduction
  • 3 AML Therapeutics Market: Market Characterization
  • 4 AML Therapeutics Market: Competitive Assessment
  • 5 AML Therapeutics Market: Pipeline Assessment
  • 6 AML Market: Implications for Future Market Competition
  • 7 AML Therapeutics Market: Future Players in the AML Therapeutics Market
  • 8 AML Market: Appendix

Companies Mentioned:

  • Genzyme
  • TopoTarget A/S
  • Vion Pharmaceutical Inc.

For more information visit http://www.researchandmarkets.com/research/353254/acute_myeloid_leuk



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.